MyMind is a life science company based in Vienna. MyMind’s first target group are children with Autism Spectrum Disorder (ASD) and then Attention Deficit Hyperactivity Disorder (ADHD). ASD is part of the personal story of the two founders as their daughter was diagnosed with ASD. ADHD often is comorbid with ASD, i.e., is diagnosed as a second disorder alongside ASD and is related to the impairment. Both groups have social behaviour issues as well as learning and concentration difficulties.
R&D:MyMind conducts research in the field of supporting people with ASD and ADHD using Neurofeedback, but also identifiying biomarkers to identify neurological issues. MyMind is also involved in other projects concerning neurological issues such as the detection of dementia at an early stage.
Production:MyMind has is building up its production facilities to produce mobile and easy to use EEGs.
Services:MyMind will offer a mobile neurofeedback therapy approx. from Q1 2022
Sales/Distribution:NA
Fuchsthallergasse 2/10
1090 Wien
Vienna
Contact: Christof Götz (Managing Director)
Email: hello@mymind.life
Website